Citation: Ld. Dresser et al., Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for thetreatment of community-acquired pneumonia, CHEST, 119(5), 2001, pp. 1439-1448
Authors:
Paladino, JA
Fong, DA
Forrest, A
Ramphal, R
Citation: Ja. Paladino et al., Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy - For the treatment of febrile episodes in neutropenic patients, PHARMACOECO, 18(4), 2000, pp. 369-381
Citation: Ja. Paladino et al., Costs and bacterial susceptibility after therapeutic interchange of fluoroquinolones, AM J HEAL S, 57(18), 2000, pp. 1712-1712
Citation: Ke. Pickerill et al., Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters, PHARMACOTHE, 20(4), 2000, pp. 417-428
Authors:
Plouffe, J
Schwartz, DB
Kolokathis, A
Sherman, BW
Arnow, PM
Gezon, JA
Suh, B
Anzuetto, A
Greenberg, RN
Niederman, M
Paladino, JA
Ramirez, JA
Inverso, J
Knirsch, CA
Citation: J. Plouffe et al., Clinical efficacy of intravenous followed by oral azithromycin monotherapyin hospitalized patients with community-acquired pneumonia, ANTIM AG CH, 44(7), 2000, pp. 1796-1802
Citation: Dj. Walters et al., Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections, PHARMACOECO, 16(5), 1999, pp. 551-561
Authors:
Rifenburg, RP
Paladino, JA
Bhavnani, SM
Den Haese, D
Schentag, JJ
Citation: Rp. Rifenburg et al., Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility, AM J HEAL S, 56(21), 1999, pp. 2217-2223